State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China; Shanghai High-Tech United Bio-Technological R&D Co., Ltd, Shanghai 201206, China.
Biomed Pharmacother. 2017 Sep;93:334-343. doi: 10.1016/j.biopha.2017.06.047. Epub 2017 Jun 24.
Hepatocellular carcinoma (HCC) is known as a highly prevalent cancer with a poor prognosis and short survival time, despite intensive research and clinical efforts. Increasing numbers of studies have reported that microRNAs are involved in the malignant behavior of hepatocellular carcinoma cells via directly targeting multiple oncogenes or tumor suppressors. Here, we report that the expression of microRNA-493 (miR-493) is decreased in HCC cell lines and in tumor tissues. Overexpression of miR-493 in HCC cells dramatically inhibited cell proliferation and colony-formation in vitro and inhibited tumor formation of HCC cell xenografts in vivo. miR-493 also suppressed cell migration and invasion in HCC cell lines. Novel targets ANTXR1 and RSPO2 were confirmed to be suppressed by miR-493 directly, and overexpression of ANTXR1 and RSPO2 could restore tumorigenesis in miR-493 treated HCC cell. Moreover, Wnt/β-catenin signaling pathway, which was reported to be activated by ANTXR1 and RSPO2, was also inhibited by miR-493 overexpression and might be involved in anti-tumor function of miR-493. These findings suggest that miR-493 acts as a negative regulator in hepatocellular carcinoma progression and may be a potential therapeutic target for HCC.
肝细胞癌 (HCC) 是一种高发癌症,预后不良,生存时间短,尽管进行了大量的研究和临床努力。越来越多的研究报告称,microRNAs 通过直接靶向多个癌基因或肿瘤抑制基因参与肝癌细胞的恶性行为。在这里,我们报告 miR-493 的表达在 HCC 细胞系和肿瘤组织中降低。在 HCC 细胞中过表达 miR-493 可显著抑制体外细胞增殖和集落形成,并抑制 HCC 细胞异种移植瘤的体内形成。miR-493 还抑制 HCC 细胞系中的细胞迁移和侵袭。新型靶标 ANTXR1 和 RSPO2 被证实可被 miR-493 直接抑制,而过表达 ANTXR1 和 RSPO2 可恢复 miR-493 处理的 HCC 细胞的致瘤性。此外,据报道,ANTXR1 和 RSPO2 激活的 Wnt/β-catenin 信号通路也被 miR-493 过表达抑制,可能参与 miR-493 的抗肿瘤功能。这些发现表明,miR-493 作为肝细胞癌进展的负调节剂发挥作用,可能是 HCC 的潜在治疗靶点。